A new injectable drug called Lepodisiran has shown to offer up to a 93.9% reduction in heart cholesterol levels. In a study, participants who received the drug experienced a significant drop in Lp(a) levels, with effects lasting up to 180 days and some patients maintaining low levels even 18 months later. Dr. Steven Nissen of the Cleveland Clinic stated that this drug could provide long-term benefits for individuals with high Lp(a) levels.